Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Atacama Labs and Excella partner to sell PDG Granule and Tablet Manufacturing Services

Atacama Labs Oy has developed an innovative oral drug delivery technology (called 'pneumatic dry granulation' or 'PDG Technology(TM)'). The technology is aimed to replace existing solid dosage form development and manufacturing methods (like wet granulation or standard roller compaction) and will help both NCE galenic developers and life cycle managers to overcome development or differentiation issues.

4 Mar 2010

University of Calgary chemist finds potential tool to measure impact of nanoparticles on human health

University of Calgary chemistry professor David Cramb is a step closer to helping solve a complex problem in nanotechnology: the impact nanoparticles have on human health and the environment.

4 Mar 2010

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, with two of the only three such products approved by the FDA for treatment of back of the eye diseases, today said that 24-month data from the FAME Phase 3 study for Iluvien presented at Angiogenesis 2010 included additional efficacy and safety data that reinforced the positive top-line results reported in December 2009 by pSivida and its licensee, Alimera Sciences, Inc.

4 Mar 2010

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

CPEX Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. For the quarter CPEX reported revenues of $5.2 million and a net loss of $498,000. For the year CPEX reported revenues of $18.7 million and a net loss of $3.0 million.

3 Mar 2010

European Journal of Drug Metabolism and Pharmacokinetics to be published by Springer

Starting in 2010, Springer will publish the European Journal of Drug Metabolism and Pharmacokinetics. All aspects of drug delivery and bioavailability are covered in the journal, which was previously published by the Swiss publisher M-decine & Hygi-ne. The journal was founded in 1975 by the late Professor Achille Benakis at the University of Geneva, Switzerland, and through the years gathered a loyal community of authors and readers.

3 Mar 2010

Unilife agrees to Exclusivity List; Sanofi-aventis secures exclusivity for Unifill syringe

Unilife Corporation, today announced that it has agreed to a list of therapeutic drug classes ("Exclusivity List") within which sanofi-aventis has the exclusive right to purchase the Unifill™ ready-to-fill syringe.

3 Mar 2010

Impax Laboratories' generic FLOMAX ANDA: FDA grants final approval

Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company’s Abbreviated New Drug Application (ANDA) for the generic version of FLOMAX® (tamsulosin hydrochloride) 0.4mg capsules. The Company also announced that it is commencing shipment through Global Pharmaceuticals, Impax’s generic division.

3 Mar 2010

Sanquin Blood Supply Foundation, Netherlands Vaccine Institute launch AmpVacs project to develop influenza A vaccine

Sanquin Blood Supply Foundation, the Netherlands Cancer Institute, and the Netherlands Vaccine Institute announce today the launch of their joint AmpVacs project aiming at the development of a broadly protective synthetic influenza A vaccine component that in combination with classical antibody-stimulating vaccines will induce protection against future influenza A threats.

2 Mar 2010

Archimedes Pharma raises GBP65 million in new funding

Archimedes Pharma, the leading specialty pharma company, today announced that it has raised GBP65 million (approx US$100 million) in new funding. The round was led by new investor Novo Growth Equity, the growth equity fund of Novo A/S, and included participation by major current investor, Warburg Pincus, a global private equity firm. Archimedes also announced the appointment of a new President and Chief Executive Officer, Jeffrey H. Buchalter, formerly President and Chief Executive Officer of US-based Enzon.

2 Mar 2010

Celsion to commence Phase II Study of ThermoDox and RFA for CRLM

Celsion Corporation today announced that it will initiate a Randomized Phase II Study of Lyso-Thermosensitive Liposomal Doxorubicin (ThermoDox®) and Radiofrequency Ablation (RFA) for Colorectal Liver Metastases (CRLM). Dr. Steven K. Libutti, Professor and Vice Chairman, Department of Surgery and Director of the Montefiore-Einstein Center for Cancer Care and Albert Einstein College of Medicine in New York City, will serve as Principal Investigator for the study.

2 Mar 2010

3M and PCTS to globally market innovative automated hand hygiene compliance solution

3M and Patient Care Technology Systems, a subsidiary of Consulier Engineering, Inc., today announced that they have signed an agreement to bring a state-of-the-art automated hand hygiene compliance solution to healthcare customers globally.

27 Feb 2010

SNI clinical study using ultrasound for treatment of ICH and IVH presented at International Stroke Conference

EKOS Corporation announced today that Dr. David W. Newell, Co–Executive Director, Swedish Neuroscience Institute (Seattle, WA) presented a SNI clinical study known as ‘SLEUTH’ (Safety of Lysis with Ultrasound in the Treatment of Intracerebral (ICH) and Intraventricular Hemorrhage (IVH) at the American Heart Association International Stroke Conference (San Antonio, TX).

26 Feb 2010

Supelco launches Ascentis Express Peptide ES-C18 HPLC columns

Supelco, a division of Sigma-Aldrich®, announced today the launch of Ascentis Express Peptide ES-C18, a high-speed, high-performance liquid chromatography (HPLC) column based on a new 160 angstrom Fused-Core™ particle design. This column design exhibits very high column efficiency, providing a stable, reversed phase packing with a pore structure and pore size that is optimized for reversed-phase HPLC separations of peptides and polypeptides.

26 Feb 2010

Impax Laboratories announces record net income of $0.61 per diluted share for fourth-quarter 2009

Impax Laboratories, Inc. today reported its strongest financial results in its history due to record sales from its Global products sales channel.

25 Feb 2010

Novartis Pharma agrees to further extend maturity date of Emisphere Technologies' Convertible Promissory Note

Emisphere Technologies, Inc., a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen® Technology, today announced that Novartis Pharma AG has agreed to further extend the maturity date of Emisphere’s Convertible Promissory Note to May 26, 2010.

25 Feb 2010

Scientists one step closer to innovative drug delivery

A team of scientists led by Dr Simon Richardson at the University of Greenwich has got a step closer to one of the holy grails of drug delivery.

25 Feb 2010

Zcube joins Mission Bay Capital Fund with $1M investment

Mission Bay Capital, LLC, has added a new limited partner to its first venture fund, bolstering the fund's ability to invest in promising bioscience companies emerging from the University of California.

25 Feb 2010

BD Biosciences initiates next-generation flow cytometer

BD Biosciences, a segment of BD, announced today the launch of the BD FACSAria™ III Cell Sorting System, a next-generation flow cytometer with the ability to run complex multicolor experiments using up to six lasers.

From BD (Becton, Dickinson and Company) 23 Feb 2010

Centric Health Resources and CHT to create sustainable healthcare system for Americans

St. Louis-based Centric Health Resources, Inc. joined the Center for Health Transformation (CHT) a high-impact collaboration of private and public sector leaders committed to creating a 21st Century Intelligent Health System that saves lives and money for all Americans.

23 Feb 2010

Head and neck tumors in close proximity to sensitive areas may lead to brain injury, visionary risk or hearing loss

When head and neck tumors - from sinus tumors to acoustic neuromas attached to the hearing and balance nerve at the base of the skull - are located in close proximity to such sensitive areas such as the brain and eyes, they are particularly dangerous due to possible brain injury, visionary risk or hearing loss.

23 Feb 2010

Drug Delivery News and Research

Further Reading

Atacama Labs and Excella partner to sell PDG Granule and Tablet Manufacturing Services

University of Calgary chemist finds potential tool to measure impact of nanoparticles on human health

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

European Journal of Drug Metabolism and Pharmacokinetics to be published by Springer

Unilife agrees to Exclusivity List; Sanofi-aventis secures exclusivity for Unifill syringe

Impax Laboratories' generic FLOMAX ANDA: FDA grants final approval

Sanquin Blood Supply Foundation, Netherlands Vaccine Institute launch AmpVacs project to develop influenza A vaccine

Archimedes Pharma raises GBP65 million in new funding

Celsion to commence Phase II Study of ThermoDox and RFA for CRLM

3M and PCTS to globally market innovative automated hand hygiene compliance solution

SNI clinical study using ultrasound for treatment of ICH and IVH presented at International Stroke Conference

Supelco launches Ascentis Express Peptide ES-C18 HPLC columns

Impax Laboratories announces record net income of $0.61 per diluted share for fourth-quarter 2009

Novartis Pharma agrees to further extend maturity date of Emisphere Technologies' Convertible Promissory Note

Scientists one step closer to innovative drug delivery

Zcube joins Mission Bay Capital Fund with $1M investment

BD Biosciences initiates next-generation flow cytometer

Centric Health Resources and CHT to create sustainable healthcare system for Americans

Head and neck tumors in close proximity to sensitive areas may lead to brain injury, visionary risk or hearing loss

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News